- Home
- ARQT vs SHOO Comparison
ARQT vs SHOO Comparison
Compare ARQT & SHOO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ARQT
- SHOO
- Stock Information
- Founded
- ARQT 2016
- SHOO 1990
- Country
- ARQT United States
- SHOO United States
- Employees
- ARQT N/A
- SHOO N/A
- Industry
- ARQT Biotechnology: Pharmaceutical Preparations
- SHOO Shoe Manufacturing
- Sector
- ARQT Health Care
- SHOO Consumer Discretionary
- Exchange
- ARQT Nasdaq
- SHOO Nasdaq
- Market Cap
- ARQT 1.7B
- SHOO 1.8B
- IPO Year
- ARQT 2020
- SHOO 1993
- Fundamental
- Price
- ARQT $14.29
- SHOO $23.52
- Analyst Decision
- ARQT Strong Buy
- SHOO Hold
- Analyst Count
- ARQT 7
- SHOO 7
- Target Price
- ARQT $18.67
- SHOO $27.83
- AVG Volume (30 Days)
- ARQT 1.5M
- SHOO 1.7M
- Earning Date
- ARQT 08-06-2025
- SHOO 07-30-2025
- Dividend Yield
- ARQT N/A
- SHOO 3.57%
- EPS Growth
- ARQT N/A
- SHOO N/A
- EPS
- ARQT N/A
- SHOO 1.28
- Revenue
- ARQT $212,819,000.00
- SHOO $2,319,527,000.00
- Revenue This Year
- ARQT $61.83
- SHOO $13.01
- Revenue Next Year
- ARQT $36.55
- SHOO $9.15
- P/E Ratio
- ARQT N/A
- SHOO $18.44
- Revenue Growth
- ARQT 100.03
- SHOO 7.97
- 52 Week Low
- ARQT $7.86
- SHOO $19.05
- 52 Week High
- ARQT $17.75
- SHOO $50.01
- Technical
- Relative Strength Index (RSI)
- ARQT 46.02
- SHOO 40.17
- Support Level
- ARQT $14.44
- SHOO $22.26
- Resistance Level
- ARQT $15.38
- SHOO $27.41
- Average True Range (ATR)
- ARQT 0.66
- SHOO 1.02
- MACD
- ARQT -0.09
- SHOO -0.33
- Stochastic Oscillator
- ARQT 10.19
- SHOO 23.33
About ARQT Arcutis Biotherapeutics Inc.
Arcutis Biotherapeutics Inc is a medical dermatology company. It is developing treatments for patients with immune-mediated dermatological diseases and conditions. It is leveraging recent advances in immunology and inflammation to develop differentiated therapies against biologically validated targets to solve persistent treatment challenges in serious diseases of the skin. The company's product candidate ZORYVE roflumilast cream, has completed pivotal Phase 3 clinical trials in plaque psoriasis, demonstrating symptomatic improvement and favorable tolerability in this population.
About SHOO Steven Madden Ltd.
Steven Madden Ltd designs and sells brand-name and private-label footwear and accessories. Its products are geared toward fashion-conscious adults and children. The company sells its products through department stores and other retailers as well as its stores and websites. The company's revenue comes from its operating segments: Wholesale Footwear, Wholesale Accessories or Apparel, Direct-to-Consumer, and Licensing. The wholesale footwear segment accounts for the majority of revenue.